February 09, 2021
We continue our coverage of Longevity Therapeutics 2021 and bring you part 2 of day 1. Read the first article of the series here. Dr. Steven Braithwhite - Chief Scientific Officer, Alkahest Steven Braithwhite from Alkahest gave an update on the company’s ongoing clinical trials. Alkahest has been sifting plasma proteome in search for proteins...
November 12, 2020
A team of researchers, including Dr. Tony Wyss-Coray, co-founder of Alkahest, has discovered that exposing young cells to aged blood causes their gene expression to become akin to aged cells. Signaling cells to act older We have known from the heterochronic parabiosis and plasmapheresis research performed by Dr. Irina Conboy's lab and similar work done...
June 03, 2020
Alkahest has announced plans to launch a Phase 2 human trial that aims to address cognitive impairment and takes the unusual approach of using an external medical device that filters a harmful protein from the blood of end-stage renal disease patients. The medical device, known as an AKST1210, will be connected in-line with a haemodialysis...
April 15, 2019
We have known since the 19th century that young blood has surprising curative and rejuvenation abilities. It's quite strange, but it happens to be true. In recent years, scientific efforts to understand what it is about young blood that causes rejuvenation have ramped up. We now know that young and old mice with surgically connected...
